Histone H1.3 suppresses H19 noncoding RNA expression and cell growth of ovarian cancer cells

Cancer Research

Volumn 74, Issue 22, 2014, Pages 6463-6473

  Medrzycki, Magdalena ^a   Zhang, Yunzhe ^a   Zhang, Weijia ^b   Cao, Kaixiang ^a   Pan, Chenyi ^a   Lailler, Nathalie ^c   McDonald, John F ^a   Bouhassira, Eric E ^d   Fan, Yuhong ^a  

^a GEORGIA INSTITUTE OF TECHNOLOGY   (United States)

^b MOUNT SINAI SCHOOL OF MEDICINE   (United States)

^c MEMORIAL SLOAN KETTERING CANCER CENTER   (United States)

^d ALBERT EINSTEIN COLLEGE OF MEDICINE   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

HISTONE H1; HISTONE H1.3; RNA H19; TRANSCRIPTION FACTOR CTCF; UNCLASSIFIED DRUG; H19 LONG NON-CODING RNA; HISTONE; LONG UNTRANSLATED RNA;

ARTICLE; CARCINOGENESIS; CELL GROWTH; COLONY FORMATION; CONTROLLED STUDY; DNA METHYLATION; FEMALE; GENE EXPRESSION; GENOME IMPRINTING; GROWTH RATE; H19 GENE; HUMAN; HUMAN CELL; IMPRINTING CONTROL REGION; NUCLEOTIDE SEQUENCE; OVARIAN CANCER CELL LINE; OVARY CANCER; OVCAR 3 CELL LINE; ANTAGONISTS AND INHIBITORS; CELL PROLIFERATION; GENE EXPRESSION REGULATION; GENETICS; OVARY TUMOR; PATHOLOGY; PHYSIOLOGY; TUMOR CELL LINE;

CELL LINE, TUMOR; CELL PROLIFERATION; DNA METHYLATION; FEMALE; GENE EXPRESSION REGULATION, NEOPLASTIC; HISTONES; HUMANS; OVARIAN NEOPLASMS; RNA, LONG NONCODING;

EID: 84918553017     PISSN: 00085472     EISSN: 15387445     Source Type: Journal    
DOI: 10.1158/0008-5472.CAN-13-2922     Document Type: Article

References (50)

1. Jemal A, Siegel R, Ward E, Hao Y, Xu J, Thun MJ. Cancer statistics, 2009. CA: Cancer J Clin 2009;59:225-49.
2. Goff BA, Mandel L, Muntz HG, Melancon CH. Ovarian carcinoma diagnosis. Cancer 2000;89:2068-75.
3. Schuijer M, Berns EM. TP53 and ovarian cancer. Human Mutation 2003;21:285-91.
4. Balch C, Fang F, Matei DE, Huang TH, Nephew KP. Minireview: Epigenetic changes in ovarian cancer. Endocrinology 2009;150:4003-11.
5. Nephew KP, Balch C, Zhang S, Huang TH. Epigenetics and ovarian cancer. Cancer Treat Res 2009;149:131-46.
6. Medrzycki M, Zhang Y, McDonald JF, Fan Y. Profiling of linker histone variants in ovarian cancer. Front Biosci (Landmark Ed) 2012;17:396-406.
7. Woodcock CL, Skoultchi AI, Fan Y. Role of linker histone in chromatin structure and function: H1 stoichiometry and nucleosome repeat length. Chromosome Res 2006;14:17-25.
8. Happel N, Doenecke D. Histone H1 and its isoforms: contribution to chromatin structure and function. Gene 2009;431:1-12.
9. Fan Y, Nikitina T, Zhao J, Fleury TJ, Bhattacharyya R, Bouhassira EE, et al. Histone H1 depletion in mammals alters global chromatin structure but causes specific changes in gene regulation. Cell 2005;123:1199-212.
10. Adriaenssens E, Dumont L, Lottin S, Bolle D, Lepretre A, Delobelle A, et al. H19 overexpression in breast adenocarcinoma stromal cells is associated with tumor values and steroid receptor status but independent of p53 and Ki-67 expression. Am J Pathol 1998;153:1597-607.
11. Ariel I, Miao HQ, Ji XR, Schneider T, Roll D, De Groot N, et al. Imprinted H19 oncofetal RNA is a candidate tumour marker for hepatocellular carcinoma. Mol Pathol 1998;51:21-5.
12. Cui H, Onyango P, Brandenburg S, Wu Y, Hsieh CL, Feinberg AP. Loss of imprinting in colorectal cancer linked to hypomethylation of H19 and IGF2. Cancer Res 2002;62:6442-6.
13. Tanos V, Prus D, Ayesh S, Weinstein D, Tykocinski ML, De-Groot N, et al. Expression of the imprinted H19 oncofetal RNA in epithelial ovarian cancer. Eur J Obstet Gynecol Reprod Biol 1999;85:7-11.
14. Matouk I, Raveh E, Ohana P, Lail RA, Gershtain E, Gilon M, et al. The increasing complexity of the oncofetal H19 gene locus: functional dissection and therapeutic intervention. Int J Mol Sci 2013;14:4298-316.
15. Gabory A, Ripoche MA, Yoshimizu T, Dandolo L. The H19 gene: regulation and function of a non-coding RNA. Cytogenet Genome Res 2006;113:188-93.
16. Ariel I, Ayesh S, Perlman EJ, Pizov G, Tanos V, Schneider T, et al. The product of the imprinted H19 gene is an oncofetal RNA. Mol Pathol 1997;50:34-44.
17. Gabory A, Ripoche MA, Le Digarcher A, Watrin F, Ziyyat A, Forne T, et al. H19 acts as a trans regulator of the imprinted gene network controlling growth in mice. Development 2009;136:3413-21.
18. Borensztein M, Monnier P, Court F, Louault Y, Ripoche MA, Tiret L, et al. Myod and H19-Igf2 locus interactions are required for diaphragm formation in the mouse. Development 2013;140:1231-9.
19. Ayesh S, Matouk I, Schneider T, Ohana P, Laster M, Al-Sharef W, et al. Possible physiological role of H19 RNA. Mol Carcinog 2002;35:63-74.
20. Keniry A, Oxley D, Monnier P, Kyba M, Dandolo L, Smits G, et al. The H19 lincRNA is a developmental reservoir of miR-675 that suppresses growth and Igf1r. Nature Cell Biol 2012;14:659-65.
21. Tsang WP, Ng EK, Ng SS, Jin H, Yu J, Sung JJ, et al. Oncofetal H19-derived miR-675 regulates tumor suppressor RB in human colorectal cancer. Carcinogenesis 2010;31:350-8.
22. Cai X, Cullen BR. The imprinted H19 noncoding RNA is a primary microRNA precursor. Rna 2007;13:313-6.
23. Berteaux N, Aptel N, Cathala G, Genton C, Coll J, Daccache A, et al. A novel H19 antisense RNA overexpressed in breast cancer contributes to paternal IGF2 expression. Mol Cell Biol 2008;28:6731-45.
24. Onyango P, Feinberg AP. A nucleolar protein, H19 opposite tumor suppressor (HOTS), is a tumor growth inhibitor encoded by a human imprinted H19 antisense transcript. Proc Natl Acad Sci U S A 2011;108:16759-64.
25. Sasaki H, Ishihara K, Kato R. Mechanisms of Igf2/H19 imprinting: DNA methylation, chromatin and long-distance gene regulation. J Biochem 2000;127:711-5.
26. Gabory A, Jammes H, Dandolo L. The H19 locus: role of an imprinted non-coding RNA in growth and development. Bioessays 2010;32:473-80.
27. Medrzycki M, Zhang Y, Cao K, Fan Y. Expression analysis of mammalian linker-histone subtypes. J Vis Exp 2012;61:e3577.
28. Franken NA, Rodermond HM, Stap J, Haveman J, Van Bree C. Clonogenic assay of cells in vitro. Nat Protoc 2006;1:2315-9.
29. Huang Da W, Sherman BT, Lempicki RA. Systematic and integrative analysis of large gene lists using DAVID bioinformatics resources. Nat Protoc 2009;4:44-57.
30. Zhang Y, Liu Z, Medrzycki M, Cao K, Fan Y. Reduction of Hox gene expression by histone H1 depletion. PLoS One 2012;7:e38829.
31. Cao K, Lailler N, Zhang Y, Kumar A, Uppal K, Liu Z, et al. Highresolution mapping of h1 linker histone variants in embryonic stem cells. PLoS Genet 2013;9:e1003417.
32. Yang Y, Hu JF, Ulaner GA, Li T, Yao X, Vu TH, et al. Epigenetic regulation of Igf2/H19 imprinting at CTCF insulator binding sites. J Cell Biochem 2003;90:1038-55.
33. Hark AT, Schoenherr CJ, Katz DJ, Ingram RS, Levorse JM, Tilghman SM. CTCF mediates methylation-sensitive enhancer-blocking activity at the H19/Igf2 locus. Nature 2000;405:486-9.
34. Bell AC, Felsenfeld G. Methylation of a CTCF-dependent boundary controls imprinted expression of the Igf2 gene. Nature 2000;405:482-5.
35. Berteaux N, Lottin S, Monte D, Pinte S, Quatannens B, Coll J, et al. H19 mRNA-like noncoding RNA promotes breast cancer cell proliferation through positive control by E2F1. J Biol Chem 2005;280:29625-36.
36. Lottin S, Adriaenssens E, Dupressoir T, Berteaux N, Montpellier C, Coll J, et al. Overexpression of an ectopic H19 gene enhances the tumorigenic properties of breast cancer cells. Carcinogenesis 2002;23:1885-95.
37. Matouk IJ, De Groot N, Mezan S, Ayesh S, Abu-Lail R, Hochberg A, et al. The H19 non-coding RNA is essential for human tumor growth. PLoS One 2007;2:e845.
38. Yang F, Bi J, Xue X, Zheng L, Zhi K, Hua J, et al. Up-regulated long noncoding RNA H19 contributes to proliferation of gastric cancer cells. FEBS J 2012;279:3159-65.
39. Luo M, Li Z, Wang W, Zeng Y, Liu Z, Qiu J. Long non-coding RNA H19 increases bladder cancer metastasis by associating with EZH2 and inhibiting E-cadherin expression. Cancer Lett 2013;333:213-21.
40. Barsyte-Lovejoy D, Lau SK, Boutros PC, Khosravi F, Jurisica I, Andrulis IL, et al. The c-Myc oncogene directly induces the H19 noncoding RNA by allele-specific binding to potentiate tumorigenesis. Cancer Res 2006;66:5330-7.
41. Li Y, Meng G, Guo QN. Changes in genomic imprinting and gene expression associated with transformation in a model of human osteosarcoma. Exp Mol Pathol 2008;84:234-9.
42. Giambra V, Volpi S, Emelyanov AV, Pflugh D, Bothwell AL, Norio P, et al. Pax5 and linker histone H1 coordinate DNA methylation and histone modifications in the 3' regulatory region of the immunoglobulin heavy chain locus. Mol Cell Biol 2008;28:6123-33.
43. Maclean JA, Bettegowda A, Kim BJ, Lou CH, Yang SM, Bhardwaj A, et al. The rhox homeobox gene cluster is imprinted and selectively targeted for regulation by histone h1 and DNA methylation. Mol Cell Biol 2011;31:1275-87.
44. Yang SM, Kim BJ, Norwood Toro L, Skoultchi AI. H1 linker histone promotes epigenetic silencing by regulating bothDNAmethylation and histone H3 methylation. Proc Natl Acad Sci U S A 2013;110:1708-13.
45. Th'ng JP, Sung R, Ye M, Hendzel MJ. H1 family histones in the nucleus. Control of binding and localization by the C-terminal domain. J Biol Chem 2005;280:27809-14.
46. Orrego M, Ponte I, Roque A, Buschati N, Mora X, Suau P. Differential affinity of mammalian histone H1 somatic subtypes for DNA and chromatin. BMC Biol 2007;5:22.
47. Vaquero A, Scher M, Lee D, Erdjument-Bromage H, Tempst P, Reinberg D. Human SirT1 interacts with histone H1 and promotes formation of facultative heterochromatin. Mol Cell 2004;16:93-105.
48. Nielsen AL, Oulad-Abdelghani M, Ortiz JA, Remboutsika E, Chambon P, Losson R. Heterochromatin formation in mammalian cells: interaction between histones and HP1 proteins. Mol Cell 2001;7:729-39.
49. Martin C, Cao R, Zhang Y. Substrate preferences of the EZH2 histone methyltransferase complex. J Biol Chem 2006;281:8365-70.
50. Hill DA, Imbalzano AN. Human SWI/SNF nucleosome remodeling activity is partially inhibited by linker histone H1. Biochemistry 2000;39:11649-56.